Mankind Pharma Assignment – Annual
Report 2024–25
Q1. What is the company's business?
Mankind Pharma Limited is a leading Indian pharmaceutical company with a diverse
portfolio that spans prescription pharmaceuticals, specialty chronic therapies, super-
specialty segments, and consumer healthcare products. The company operates with a
mission to provide high-quality, affordable, and accessible medicines. With a bottom-up
approach, it built a strong pan-India presence, especially in underserved regions. Over time,
Mankind expanded into chronic therapies like cardiology, neurology, and urology, and
recently ventured into high-entry-barrier super-specialty segments through acquisitions
like Bharat Serums & Vaccines (BSV). Its consumer healthcare vertical includes market-
leading brands in pregnancy kits, condoms, anti-acne products, and antacids. Mankind also
emphasizes strong in-house R&D, quality manufacturing, and digital transformation to drive
growth.
Q2. What industry does the company belong to, and what is its position in the
industry?
Industry: Pharmaceutical and Healthcare (Prescription drugs + OTC + Super Specialty)
Position in the Industry:
- #4 by value (market share: 4.8%) in the Indian Pharma Market (IPM)
- #2 by volume (market share: 6.0%)
- #1 in prescription share for the last 8 years
Competitor Analysis:
| Company | Rank by Value | Market Share | Focus Area |
|------------------------|---------------|--------------|---------------------------------------|
| Sun Pharma |1 | Highest | Specialty, chronic, and global ops |
| Cipla |2 | High | Respiratory, US generics |
| Zydus Lifesciences | 3 | Moderate | Chronic, biosimilars |
| Mankind Pharma |4 | 4.8% | Acute + Chronic, OTC, BSV (Super Spec)|
| Dr. Reddy’s Laboratories | 5 | Moderate | Generics, injectables, global reach
Q3. What are its main products and services? Name some brands.
Main Products/Services:
Pharmaceuticals: The company manufactures variety of pharmaceutical
formulations for broad spectrum of acute and chronic therapeutic segments.
Consumer Healthcare: Mankind Pharma is also active in the consumer healthcare
(over-the-counter or OTC) segment, offering products for a broad range of wellness
needs.
Super Specialty: The company also includes products, largely in women's health,
fertility, and critical care, after acquiring Bharat Serums and Vaccines Limited (BSV)
in 2024.
The company also has ventures in animal health and ayurveda products.
Some Mankind Pharma Limited products include the following:
Manforce: A condom brand that is ranked #1 in the market due to its large market
share
Prega News: A brand producing pregnancy test kit that is ranked first in the
category of pregnancy kits in market.
Unwanted-72: brand for emergency contraceptive ranked first in its category in
market.
Gaso-Fast: An brand producing antacid powder that holds second rank first its
category market.
AcneStar: A medicated brand for anti-acne, ranked first in its category in market.
HealthOK: A brand producing multivitamins, ranked eight in its category in market.
Nimulid: A brand producing pain/analgesics.
Dydroboon: An in -house product for Dydrogesterone
Nurokind: Brand Family which includes Nurokind Gold.
Telmikind: A cardiological therapy brand family.
Moxikind: A class of anti-infectives.
Neptaz: An in-house licensed cardiac product.
Foligraf: Fertility brand from the super-specialty segment.
Antid: A women's health brand belonging to the super-specialty portfolio as well.
Humog: A fertility brand.
Symbicort: An asthma inhaler in-licensed from AstraZeneca.
Q4. Dividend for current and previous year; compute the change
The Board of your Company has not declared any dividend for the financial year 2024-25.
The Board of your Company has not declared any dividend for the financial year 2023-24.
Hence change is 0.
Q5. Significant Public Information Since June 1, 2024
- Acquisition of Bharat Serums & Vaccines (BSV):
- Date: October 23, 2024
- Value: ₹13,768 crore
- Launch of Crenzlo (Inclisiran):
- In-licensed from Novartis
- For lipid management therapy
- Partnership with Innovent Biologics:
- To commercialize Sintilimab, a PD-1 immunotherapy in India
Reference: Annual Report 2024–25, Business Today (June 2025)
Q6. Business Responsibility and Sustainability Reporting (BRSR) – 3 Key Items &
Implications
1. Plastic Neutrality & Renewable Energy Use:
- 100% plastic neutrality, 92% renewable energy usage.
- Implication: Strong ESG credentials attract sustainability-focused investors.
2. Employee Well-being and Safety:
- 2,000+ training sessions, ISO 27001 certified, zero LTIFR.
- Implication: Reliable operations and workforce capability enhancement.
3. Sustainable Packaging and Waste Management:
- 55% waste co-processed; green chemistry adoption.
- Implication: Improved operational efficiency and environmental stewardship.
Q7. Corporate Social Responsibility Report – 3 Key Highlights
1. Mobile Surgical Units for Indian Army in Ladakh – Supporting border health
infrastructure.
2. Support to Tata Memorial Cancer Institute – Oncology care enhancement.
3. 'Kind Care' WOS – Focused CSR arm for healthcare access and community support.
Q8. Management Discussion and Analysis (MDA) – 3 Key Highlights
1. Chronic Segment Growth:
- Share increased to 37%; projected >40%
- Implication: High-margin, steady revenue driver
2. BSV Acquisition:
- Strengthens IVF, critical care, super-specialty presence
- Implication: Entry into high-growth, less competitive markets
3. AI-Driven Supply Chain & Digital Tech:
- Use of ADAPT, PACE, and Wave systems
- Implication: Greater operational control, cost-efficiency, agility
